Active immunization against (Pro3)GIP improves metabolic status in high-fat-fed mice

Diabetes, Obesity and Metabolism

Volumn 12, Issue 9, 2010, Pages 744-751

  Montgomery, I A ^a   Irwin, N ^a   Flatt, P R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Active immunization; Gastric inhibitory polypeptide (GIP); GIP antibody; Glucose homeostasis; Insulin secretion

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE[3 PROLINE]; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE ANTIBODY; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUTRALIZING ANTIBODY; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; GASTRIC INHIBITORY POLYPEPTIDE; LIPID; PRO GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE; PRO-GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HORMONE RESPONSE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LEAN BODY WEIGHT; LIPID DIET; LIPID LIVER LEVEL; MALE; METABOLIC DISORDER; MOUSE; NONHUMAN; OBESITY; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; FAT INTAKE; IMMUNOLOGY; INSULIN RESISTANCE; METABOLISM; PANCREAS; PHYSIOLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; BLOOD GLUCOSE; BODY WEIGHT; DIETARY FATS; GASTRIC INHIBITORY POLYPEPTIDE; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; MICE; OBESITY; PANCREAS;

EID: 77955027548     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01228.x     Document Type: Article

References (24)

1. Lean M, Finer N. ABC of obesity. Management: part II-drugs. BMJ 2006, 333:794-797.
2. Blackburn GL. Solutions in weight control: lessons from gastric surgery. Am J Clin Nutr 2005, 82:248S-252S.
3. Irwin N, Flatt PR. Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia 2009, 52:1724-1731.
4. Irwin N, McClean PL, Patterson S, Hunter K, Flatt PR. Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes. Biol Chem 2009, 390:75-80.
5. Irwin N, Flatt PR, Gault VA. GIP-based therapeutics for diabetes and obesity. Curr Chem Biol 2007, 2:61-68.
6. Yip RG, Boylan MO, Kieffer TJ, Wolfe MM. Functional GIP receptors are present on adipocytes. Endocrinology 1998, 139:4004-4007.
7. Ross SA, Dupre J. Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects. Diabetes 1978, 27:327-333.
8. Flatt PR, Bailey CJ, Kwasowski P, Swanston-Flatt SK, Marks V. Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice. Diabetes 1983, 32:433-435.
9. Flatt PR, Bailey CJ, Kwasowski P, Page T, Marks V. Plasma immunoreactive gastric inhibitory polypeptide in obese hyperglycaemic (ob/ob) mice. J Endocrinol 1984, 101:249-256.
10. Bailey CJ, Flatt PR, Kwasowski P, Powell CJ, Marks V. Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in obese hyper- glycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets. Acta Endocrinol (Copenh) 1986, 112:224-229.
11. Miyawaki K, Yamada Y, Ban N. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002, 8:738-742.
12. Zhou H, Yamada Y, Tsukiyama K. Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action. Biochem Biophys Res Commun 2005, 335:937-942.
13. McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab 2007, 293:E1746-E1755.
14. Hansotia T, Maida A, Flock G. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 2007, 117:143-152.
15. Gault VA, O'Harte FP, Harriott P, Flatt PR. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem Biophys Res Commun 2002, 290:1420-1426.
16. Gault VA, Irwin N, Green BD. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 2005, 54:2436-2446.
17. Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 2007, 50:1752-1762.
18. Irwin N, McClean PL, O'Harte FP, Gault VA, Harriott P, Flatt PR. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia 2007, 50:1532-1540.
19. Althage MC, Ford EL, Wang S, Tso P, Polonsky KS, Wice BM. Targeted ablation of GIP-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J Biol Chem 2008, 283:18365-18376.
20. Tsubamoto Y, Nakamura T, Kinoshita H, Tanimoto H, Noda H. Novel low-molecular weight antagonist of glucose-dependent insulinotropic polypeptide receptor, SKL14959, prevents obesity and insulin resistance. Diabetologia 2008, 51:S373.
21. Flatt PR, Bailey CJ. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 1981, 20:573-577.
22. Gault VA, O'Harte FP, Flatt PR. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? Neuropeptides 2003, 37:253-263.
23. Ebert R, Illmer K, Creutzfeldt W. Release of gastric inhibitory polypeptide (GIP) by intraduodenal acidification in rats and humans and abolishment of the incretin effect of acid by GIP-antiserum in rats. Gastroenterology 1979, 76:515-523.
24. Kim SJ, Nian C, McIntosh CH. Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade. J Biol Chem 2007, 282:8557-8567.